INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia
Tóm tắt
Tyrosine kinase inhibitors have improved survival for patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). However, prognosis for old or unfit patients remains poor. In the INCB84344-201 (formerly GIMEMA LAL 1811) prospective, multicenter, phase 2 trial, we tested the efficacy and safety of ponatinib plus prednisone in newly diagnosed patients with Ph+ ALL ≥60 years, or unfit for intensive chemotherapy and stem cell transplantation. Forty-four patients received oral ponatinib 45 mg/d for 48 weeks (core phase), with prednisone tapered to 60 mg/m2/d from days-14-29. Prophylactic intrathecal chemotherapy was administered monthly. Median age was 66.5 years (range, 26-85). The primary endpoint (complete hematologic response [CHR] at 24 weeks) was reached in 38/44 patients (86.4%); complete molecular response (CMR) in 18/44 patients (40.9%) at 24 weeks. 61.4% of patients completed the core phase. As of 24 April 2020, median event-free survival was 14.31 months (95% CI 9.30-22.31). Median overall survival and duration of CHR were not reached; median duration of CMR was 11.6 months. Most common treatment-emergent adverse events (TEAEs) were rash (36.4%), asthenia (22.7%), alanine transaminase increase (15.9%), erythema (15.9%), and γ-glutamyltransferase increase (15.9%). Cardiac and vascular TEAEs occurred in 29.5% (grade ≥3, 18.2%) and 27.3% (grade ≥3, 15.9%), respectively. Dose reductions, interruptions, and discontinuations due to TEAEs occurred in 43.2%, 43.2%, and 27.3% of patients, respectively; 5 patients had fatal TEAEs. Ponatinib and prednisone showed efficacy in unfit patients with Ph+ ALL; however, a lower ponatinib dose may be more appropriate in this population. This trial was registered at www.clinicaltrials.gov as #NCT01641107.
Từ khóa
Tài liệu tham khảo
Chiaretti, 2013, Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts, Haematologica., 98, 1702, 10.3324/haematol.2012.080432
Gleissner, 2002, Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis, Blood., 99, 1536, 10.1182/blood.V99.5.1536
Faderl, 2000, Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia, Leuk Lymphoma., 36, 263, 10.3109/10428190009148847
Faderl, 1998, Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia, Blood., 91, 3995, 10.1182/blood.V91.11.3995
Ravandi, 2009, Philadelphia chromosome-positive acute lymphoblastic leukemia, Hematol Oncol Clin North Am., 23, 1043, 10.1016/j.hoc.2009.07.007
Wassmann, 2002, Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL), Leukemia., 16, 2358, 10.1038/sj.leu.2402770
Wassmann, 2003, A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10), Ann Hematol., 82, 716, 10.1007/s00277-003-0728-8
Ottmann, 2002, A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias, Blood., 100, 1965, 10.1182/blood-2001-12-0181
Chalandon, 2015, Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia, Blood., 125, 3711, 10.1182/blood-2015-02-627935
Chiaretti, 2016, A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study, Haematologica., 101, 1544, 10.3324/haematol.2016.144535
Foà, 2011, Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, Blood., 118, 6521, 10.1182/blood-2011-05-351403
Vignetti, 2007, Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) LAL0201-B protocol, Blood., 109, 3676, 10.1182/blood-2006-10-052746
Martinelli, 2014, Extremely high rate of complete hematological response of elderly Ph+ acute lymphoblastic leukemia (ALL) patients by innovative sequential use of Nilotinib and Imatinib. A GIMEMA Protocol LAL 1408 [abstract], Cancer Res., 74, 5552, 10.1158/1538-7445.AM2014-5552
Daver, 2015, Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, Haematologica., 100, 653, 10.3324/haematol.2014.118588
Bassan, 2010, Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00, J Clin Oncol., 28, 3644, 10.1200/JCO.2010.28.1287
Tanguy-Schmidt, 2013, Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study, Biol Blood Marrow Transplant., 19, 150, 10.1016/j.bbmt.2012.08.021
Lickliter, 2015, An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial, Leuk Lymphoma., 56, 630, 10.3109/10428194.2014.925547
Ribera, 2010, Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: final results of the CSTIBES02 trial, Haematologica., 95, 87, 10.3324/haematol.2009.011221
Kim, 2015, Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia, Blood., 126, 746, 10.1182/blood-2015-03-636548
Ravandi, 2010, First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia, Blood., 116, 2070, 10.1182/blood-2009-12-261586
Yoon, 2016, Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia, Ann Oncol., 27, 1081, 10.1093/annonc/mdw123
Ravandi, 2015, Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, Cancer., 121, 4158, 10.1002/cncr.29646
Rousselot, 2016, Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL, Blood., 128, 774, 10.1182/blood-2016-02-700153
Ottmann, 2007, Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), Cancer., 109, 2068, 10.1002/cncr.22631
Soverini, 2013, Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain, Blood., 122, 1634, 10.1182/blood-2013-03-487728
Soverini, 2014, Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: the main changes are in the type of mutations, but not in the frequency of mutation involvement, Cancer., 120, 1002, 10.1002/cncr.28522
Soverini, 2009, Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors, Blood., 114, 2168, 10.1182/blood-2009-01-197186
Cortes, 2012, Ponatinib in refractory Philadelphia chromosome-positive leukemias, N Engl J Med., 367, 2075, 10.1056/NEJMoa1205127
Soverini, 2011, Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis, Haematologica., 96, 552, 10.3324/haematol.2010.034173
Soverini, 2016, Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients, Leukemia., 30, 1615, 10.1038/leu.2016.17
O’Hare, 2009, AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance, Cancer Cell., 16, 401, 10.1016/j.ccr.2009.09.028
O’Hare, 2011, Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia, Clin Cancer Res., 17, 212, 10.1158/1078-0432.CCR-09-3314
Seymour, 2014, A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, Blood Cancer J., 4, e238, 10.1038/bcj.2014.60
Parker, 2016, The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib, Blood., 127, 1870, 10.1182/blood-2015-09-666214
Shah, 2013, Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study, Br J Haematol., 162, 548, 10.1111/bjh.12382
Incyte Biosciences Distribution
Jabbour, 2018, Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study, Lancet Haematol., 5, e618, 10.1016/S2352-3026(18)30176-5
Sasaki, 2016, Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis, Cancer., 122, 3650, 10.1002/cncr.30231
Arber, 2016, The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood., 127, 2391, 10.1182/blood-2016-03-643544
Baccarani, 2006, Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet, Blood., 108, 1809, 10.1182/blood-2006-02-005686
Baccarani, 2009, Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet, J Clin Oncol., 27, 6041, 10.1200/JCO.2009.25.0779
Brookmeyer, 1982, A confidence interval for the median survival time, Biometrics., 38, 29, 10.2307/2530286
Harris, 2009, Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support, J Biomed Inform., 42, 377, 10.1016/j.jbi.2008.08.010
Chiaretti, 2015, Multicenter total therapy Gimema LAL 1509 protocol for de novo adult Ph+ acute lymphoblastic leukemia (ALL) patients. Updated results and refined genetic-based prognostic stratification, Blood., 126, 81, 10.1182/blood.V126.23.81.81
Foà, 2020, Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults, N Engl J Med., 383, 1613, 10.1056/NEJMoa2016272
Leonard, 2016, Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia, Sci Transl Med., 8, 354ra114, 10.1126/scitranslmed.aaf5309
Short, 2021, An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia, Am J Hematol., 96, E229, 10.1002/ajh.26175
Chiaretti, 2021, Updated results of the Gimema LAL2116, D-Alba trial, for newly diagnosed adults with Ph+ ALL. Presented at the European Hematology Association
Assi, 2017, Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia, Clin Lymphoma Myeloma Leuk., 17, 897, 10.1016/j.clml.2017.08.101
Cortes, 2018, Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial, Blood., 132, 393, 10.1182/blood-2016-09-739086
Cortes, 2021, OPTIC primary analysis: a dose-optimization study of 3 starting doses of ponatinib (PON) [abstract], J Clin Oncol., 39, 7000, 10.1200/JCO.2021.39.15_suppl.7000
Jabbour, 2015, Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study, Lancet Oncol., 16, 1547, 10.1016/S1470-2045(15)00207-7
Wang, 2017, T315L: a novel mutation within BCR-ABL kinase domain confers resistance against ponatinib, Leuk Lymphoma., 58, 1733, 10.1080/10428194.2016.1251591
Pemovska, 2015, Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation, Nature., 519, 102, 10.1038/nature14119
Zabriskie, 2016, Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia, Leukemia., 30, 1418, 10.1038/leu.2015.318
Leonard, 2018, Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: current evidence, and improving outcomes going forward, Curr Hematol Malig Rep., 13, 329, 10.1007/s11899-018-0462-x
Wetzler, 2014, Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance), Haematologica., 99, 111, 10.3324/haematol.2013.085811
Wieduwilt, 2018, A phase II study of dasatinib and dexamethasone as primary therapy followed by transplantation for adults with newly diagnosed Ph/BCR-ABL1-positive acute lymphoblastic leukemia (Ph+ ALL): final results of Alliance/CALGB study 10701, Blood., 132, 309, 10.1182/blood-2018-99-120029
Martinelli, 2017, Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study, J Clin Oncol., 35, 1795, 10.1200/JCO.2016.69.3531
Kantarjian, 2012, Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study, Lancet Oncol., 13, 403, 10.1016/S1470-2045(11)70386-2